GeorgeWildingMD

Vice Provost of Clinical and Interdisciplinary Research, The University of Texas MD Anderson Cancer Center, Professor ad interim, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,

Join to view full profile

Are you Dr. Wilding?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 49 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-262-1982
Is this information wrong?

Summary

Dr. George Wilding, MD is an oncologist in Madison, Wisconsin. He is currently licensed to practice medicine in Wisconsin, Texas, and Illinois. He is a Vice Provost of Clinical and Interdisciplinary Research at Department of Genitourinary Medical Oncology.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
UMass Chan Medical SchoolResidency, Internal Medicine, 1980 - 1983
University of Massachusetts Medical SchoolClass of 1980

Certifications & Licensure

WI State Medical License 1988 - 2025
TX State Medical License 2018 - 2025
MA State Medical License 1981 - 2017
IL State Medical License 1996 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013

Clinical Trials

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma Start of enrollment: 1995 Mar 01
Completed
Phase 1
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Start of enrollment: 1995 May 01
Completed
Phase 3
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 1996 Jan 01
Completed
Phase 3
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer Start of enrollment: 1996 Oct 01
Completed
Phase 3
Penclomedine in Treating Patients With Solid Tumors or Lymphoma Start of enrollment: 1997 Oct 01
Completed
Phase 1
Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 1998 Feb 01
Completed
Phase 2
Flavopiridol in Treating Patients With Recurrent Prostate Cancer Start of enrollment: 1998 May 01
Completed
Phase 2
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer Start of enrollment: 2001 Aug 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery Start of enrollment: 2002 Jun 01
Completed
Phase 1
Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Oct 01
Completed
Phase 1
3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors Start of enrollment: 2004 Jan 01
Completed
Phase 1
Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors Start of enrollment: 2004 Mar 01
Completed
Phase 1
Study of Satraplatin (JM-216) in Combination With Docetaxel Start of enrollment: 2007 Mar 01
Terminated
Phase 1
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors Start of enrollment: 2005 Jul 01
Completed
Phase 1
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma Start of enrollment: 2006 May 01
Terminated
Phase 1
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors Start of enrollment: 2007 May 22
Completed
Phase 1
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 1
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer Start of enrollment: 2002 Apr 01
Terminated
Phase 2
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine Start of enrollment: 2007 Apr 01
Completed
Phase 1
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors Start of enrollment: 2010 Jan 01
Completed
Phase 1
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2010 Sep 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

11 citations
Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
Hirak Basu, Nathaniel Wilganowski, Samantha Robertson, James M. Reuben, Evan N. Cohen, Amado J. Zurita, Sumankalai Ramachandran, Lianchun Xiao, Mark Titus, George Wilding> ;The Prostate. 2021 Jun 25
1 citations
A Festschrift in Honor of Edward M. Messing, MD, FACS.
Jean V. Joseph, R.A. Brasacchio, Chunkit Fung, Jay E. Reeder, Kevin Bylund, Deepak M. Sahasrabudhe, Shuyuan Yeh, Ahmed Ghazi, Patrick J. Fultz, Deborah J. Rubens, Guan...> ;Bladder Cancer. 2018 Oct 3
9 citations
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.
Andrew J. Armstrong, Emmanuel S. Antonarakis, Mary-Ellen Taplin, William Kevin Kelly, Himisha Beltran, Karim Fizazi, W. L. Dahut, N.D. Shore, Susan F. Slovin, Daniel J...> ;Annals of Oncology. 2018 Jan 1
1 citations
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
Yu-Ning Wong, Judith Manola, Gary R. Hudes, Bruce J. Roth, Judd W. Moul, Andrea M. Barsevick, Richard Scher, Michael J. Volk, David J. Vaughn, Stephen D. Williams, Mic...> ;Clinical Genitourinary Cancer. 2018 Apr 1
23 citations
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.
Chad Tang, Steven I. Sherman, Mellanie Price, Jun Weng, Suzanne E. Davis, David S. Hong, James C. Yao, Aman U. Buzdar, G. Wilding, J. Jack Lee> ;Clinical Cancer Research. 2017 Mar 15
1 citations
Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center.
Jeff A. Engle, Anne M. Traynor, Toby C. Campbell, Kari B. Wisinski, Noelle K. LoConte, Glenn Liu, G. Wilding, Jill M. Kolesar> ;Journal of Oncology Pharmacy Practice. 2018 Jul 1
917 citations
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher, Michael J. Morris, Walter M. Stadler, Celestia S. Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, Tomasz M. Beer, Michael A. Carducci, Kim...> ;Journal of Clinical Oncology. 2016 Sep 27
436 citations
Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
Naomi B. Haas, Judith Manola, Robert G. Uzzo, Keith T. Flaherty, Christopher G. Wood, Christopher J. Kane, Michael A.S. Jewett, Janice P. Dutcher, Michael B. Atkins, M...> ;Lancet. 2016 May 14
100 citations
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic so...
Devalingam Mahalingam, George Wilding, Samuel R. Denmeade, J. Sarantopoulas, David Cosgrove, Jeremy Cetnar, Nilofer S. Azad, Justine Yang Bruce, Michael R. Kurman, V. ...> ;British Journal of Cancer. 2016 Apr 26
16 citations
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib
Ying Chen, Brian I. Rini, Robert J. Motzer, Janice P. Dutcher, Olivier Rixe, George Wilding, Walter M. Stadler, Jamal Tarazi, May Garrett, Yazdi K. Pithavala> ;Targeted Oncology. 2016 Apr 1
41 citations
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Dustin A. Deming, Ludmila L. Cavalcante, Sam J. Lubner, Daniel Mulkerin, Noelle K. LoConte, Jens C. Eickhoff, Jill M. Kolesar, Suzanne Fioravanti, Tim F. Greten, Kathr...> ;Investigational New Drugs. 2016 Apr 1
7 citations
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin e 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer
Christos Kyriakopoulos, Elisabeth I. Heath, Jens C. Eickhoff, Jill M. Kolesar, Mulusew Yayehyirad, Thomas Moll, George Wilding, Glenn Liu> ;Investigational New Drugs. 2016 Feb 29
6 citations
Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).
Michael A. Carducci, Judith Manola, Suresh G. Nair Md, Glenn Liu, Steven R. Rousey, Janice P. Dutcher, George Wilding> ;Clinical Genitourinary Cancer. 2015 Dec 1
A phase i study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer
Kari B. Wisinski, Wendy M. Ledesma, Jill M. Kolesar, George Wilding, Glenn Liu, Jeffrey A. Douglas, Anne M. Traynor, Mark R. Albertini, Daniel Mulkerin, Howard H. Bailey> ;Journal of Oncology Pharmacy Practice. 2015 Dec 1
46 citations
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Naomi B. Haas, Judith Manola, Bonnie Ky, Keith T. Flaherty, Robert G. Uzzo, Christopher J. Kane, Michael A.S. Jewett, Lori Wood, Christopher G. Wood, Michael B. Atkins...> ;Clinical Cancer Research. 2015 Sep 15
11 citations
Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phos...
Farideh Mehraein-Ghomi, Dawn R. Church, Cynthia L. Schreiber, Ashley M. Weichmann, Hirak S. Basu, G. Wilding> ;Genes & Cancer. 2015 Sep 1
30 citations
Expression of spermidine/spermine N1‐acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis
Wei Huang, Jens C. Eickhoff, Farideh Mehraein-Ghomi, Dawn R. Church, George Wilding, Hirak S. Basu> ;The Prostate. 2015 Aug 1
34 citations
Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species
Sheng-Xiong Huang, Bong Sik Yun, Ming Ma, Hirak S. Basu, Dawn R. Church, Gudrun Ingenhorst, Yong Huang, Dong Yang, Jeremy R. Lohman, Gong-Li Tang, Jianhua Ju, Tao Liu,...> ;Proceedings of the National Academy of Sciences of the United States of America. 2015 Jul 7
9 citations
Potential cytochrome P-450 drug–drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials
Kari B. Wisinski, Colby A. Cantu, Jens C. Eickhoff, Kurt Osterby, Amye J. Tevaarwerk, Jennifer Heideman, Glenn Liu, George Wilding, Susan Johnston, Jill M. Kolesar> ;American Journal of Health-System Pharmacy. 2015 Jun 1
36 citations
A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: E...
Robert S. DiPaola, Yu-Hui Chen, Glenn J. Bubley, Mark N. Stein, Noah M. Hahn, Michael A. Carducci, Edmund C. Lattime, James L. Gulley, Philip M. Arlen, Lisa H. Butterf...> ;European Urology. 2015 Sep 1
39 citations
Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
Douglas G. McNeel, Jordan T. Becker, Jens C. Eickhoff, Laura E. Johnson, Eric S. Bradley, Isabel F. Pohlkamp, Mary Jane Staab, Glenn Liu, George Wilding, Brian M. Olson> ;Clinical Cancer Research. 2014 Jul 15
9 citations
Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression.
Farideh Mehraein-Ghomi, Stacy J. Kegel, Dawn R. Church, Joseph S. Schmidt, Quentin R. Reuter, Elizabeth L. Saphner, Hirak S. Basu, George Wilding> ;The Prostate. 2014 May 1
36 citations
A phase i study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
William R. Schelman, Tabraiz A. Mohammed, Anne M. Traynor, Jill M. Kolesar, Rebecca Marnocha, Jens C. Eickhoff, Michael D. Keppen, Dona Alberti, George Wilding, Naoko ...> ;Investigational New Drugs. 2014 Apr 1
34 citations
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors
Dustin A. Deming, Jacob Ninan, Howard H. Bailey, Jill M. Kolesar, Jens C. Eickhoff, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Dona Alberti, Rebecca Marnocha, I...> ;Investigational New Drugs. 2014 Jan 1
174 citations
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
John C. Araujo, Geralyn C. Trudel, Fred Saad, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt, George Wilding, John McCaffrey, Sergio Vicente Serrano, Vsevolod Matve...> ;The Lancet. Oncology. 2013 Dec 1
Join now to see all

Press Mentions

How Unexpected Results Can Lead Cancer Research and Treatment in New DirectionsJanuary 7th, 2019
Intermittent Androgen Deprivation Not Equivalent to Continuous Treatment for Prostate Cancer, May Compromise SurvivalApril 5th, 2013

Professional Memberships

American Society of Clinical Oncology - ASCO
Member